Foundayo's Aggressive $149/Month Price Tag Revealed; Lilly Expands AC Immune Partnership
LLY sits 49% above its 52-week low of $623.78.
Summary
Eli Lilly's newly FDA-approved weight-loss drug, Foundayo, will carry an aggressive self-pay price of approximately $149 per month for its lowest dose, a key detail following its regulatory clearance reported on April 1st. This competitive pricing strategy is expected to significantly enhance market accessibility and adoption for the oral medication, building on Lilly's strong position in the obesity market. Additionally, Lilly has expanded its partnership with AC Immune, making a CHF10 million upfront payment and committing to potential milestones exceeding CHF1.7 billion, alongside low-double-digit tiered royalties. This substantial collaboration strengthens Lilly's pipeline, particularly in neurodegenerative diseases, with IND-enabling studies planned for the first half of 2026. Traders will be watching market penetration for Foundayo and further developments from the AC Immune pact.
At the time of this announcement, LLY was trading at $931.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $879.7B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.